Assessing the biocompatibility and stability of CeO nanoparticle conjugates with azacrowns for use as radiopharmaceuticals.

The application of nanoparticles is promising for the purposes of nuclear medicine due to the possibilities of using them as vectors and transporters of radionuclides. In this study, we have successfully synthesised conjugates of CeO nanoparticles and azacrown ligands. Then, the radiolabelling conditions with radionuclides Zn, Sc and Bi were selected and the kinetic stability of the complexes in biologically significant media was evaluated.

Labeling and receptor affinity of an ultra-short somatostatin analogue Thz-Phe-D-Trp-Lys-Thr-DOTA.

Somatostatin analogues play an important role in the therapy of neuroendocrine tumors by binding to somatostatin receptors on the surface of cancer cells. In this work, we analyze the receptor-binding affinity and in vitro stability of a novel ultra-short somatostatin analogue Thz-Phe-D-Trp-Lys-Thr-DOTA (DOTA-P4). This conjugate is successfully radiolabeled with Sc, Y, Eu, and Bi, characterized and validated by thin layer and high-performance liquid chromatography.

From octreotide to shorter analogues: Synthesis, radiolabeling, stability.

This study aims at analyzing complexation properties of two new short somatostatin analogues, their synthesis, radiolabeling with Sc, Bi, and Eu and stability in vitro. Short tetrapeptide Phe-d-Trp-Lys-Thr and pentapeptide Thz-Phe-d-Trp-Lys-Thr were first conjugated with the DOTA macrocyclic chelator. These conjugates were radiolabeled with Sc, Bi, and Eu and characterized by thin-layer chromatography (TLC) and HPLC.